



## Experimental & Investigational Services Medical Necessity Guideline

<b>Medical Necessity Guideline (MNG) Title: Experimental &amp; Investigational Services</b>		
<b>MNG #: 010</b>	<input checked="" type="checkbox"/> SCO <input checked="" type="checkbox"/> One Care <input checked="" type="checkbox"/> MA Medicare Premier <input checked="" type="checkbox"/> MA Medicare Value <input checked="" type="checkbox"/> RI Medicare Preferred <input checked="" type="checkbox"/> RI Medicare Value <input checked="" type="checkbox"/> RI Medicare Maximum	<b>Prior Authorization Needed?</b> <input checked="" type="checkbox"/> Yes (always required) <input type="checkbox"/> Yes (only in certain situations. See this MNG for details) <input type="checkbox"/> No
<b>Clinical:</b> <input checked="" type="checkbox"/>	<b>Operational:</b> <input type="checkbox"/>	<b>Informational:</b> <input type="checkbox"/>
<b>Benefit Type:</b> <input type="checkbox"/> Medicare <input type="checkbox"/> Medicaid	<b>Approval Date:</b> 1/28/2019; 10/12/23; 11/9/23	<b>Effective Date:</b> 4/01/2019; 10/12/23; 11/9/23; 1/1/24; 5/9/24, 7/13/24
<b>Last Revised Date:</b> 1/29/2019; 08/05/2020, 10/16/2020; 11/05/2020; 04/01/2021; 05/13/2021; 05/18/2021; 08/04/2021; 08/19/2021; 9/2/2021; 6/2/2022; 1/11/2023; 4/13/2023; 7/13/2023; 10/12/2023; 11/9/23; 5/9/24, 7/13/24	<b>Next Annual Review Date:</b> 08/05/2021; 11/05/2021; 04/01/2022; 05/13/2022; 05/18/2022; 08/04/2022; 08/19/2022; 9/2/2022; 6/2/2023; 1/11/2024; 4/13/2024; 7/13/2024; 10/12/2024; 11/9/24	<b>Retire Date:</b>

### OVERVIEW:

*Experimental, investigational, or unproven service (EIS)* may refer to a service (e.g., treatment), procedure (e.g., test or intervention), or supply (e.g., drug, device, or equipment) that is not accepted by the professional medical community as the standard practice or therapy. Commonly, there is insufficient *authoritative or reliable evidence* for the EIS and its absolute risk (in terms of safety and effectiveness) to permit conclusions to be drawn for the effect of the treatment on health outcomes. As such, the EIS is part of ongoing studies to determine its safety, effectiveness, toxicity, maximum tolerated dose, and efficacy compared to a generally accepted means of diagnosis or treatment.

To make coverage determinations on EIS, Commonwealth Care Alliance (CCA) will utilize pertinent medical necessity guidelines; and review related information from government regulatory bodies, accrediting organizations, and scientific evidence. This may include guidance from the Center for Medicare and Medicaid Services (CMS), Food and Drug Administration (FDA), MassHealth, InterQual, National Committee for Quality Assurance (NCQA), authoritative or reliable evidence, and actively practicing specialty physicians. This will ensure that the coverage of EIS is consistent and clinically appropriate (in terms of type, frequency, extent, site, and duration) for the prevention, diagnosis, and treatment of the condition (which includes disease, illness, or disability).

### DEFINITIONS:

**Authoritative or Reliable Evidence:** Authoritative or reliable evidence refer to:

- Reports and articles that are derived from well-designed, well-conducted and scientifically valid studies that are published in credible, medical, and scientific research journals,
- Peer-reviewed publications that have been assessed by medical or scientific experts prior to publication,
- Evaluations of evidence that have considered the consistency of results and quality of published studies,

## Experimental & Investigational Services Medical Necessity Guideline

- Guidelines and recommendations made by national medical associations, reputable technology assessment bodies, and healthcare professionals with recognized clinical expertise in treating the medical condition and/or providing the treatment.
- Examples of acceptable sources of peer-reviewed medical literature include (this is not an exhaustive list):
  - American Journal of Medicine
  - Annals of Internal Medicine
  - Annals of Oncology
  - Annals of Surgical Oncology
  - Blood
  - British Medical Journal
  - The Journal of the American Medical Association
  - Journal of Clinical Oncology
  - Journal of the National Cancer Institute
  - Journal of Urology
  - Lancet
  - The New England Journal of Medicine
  - Annals of General Surgery

**Experimental, Investigational or Unproven Services (EIS):** Experimental, investigational, or unproven services may refer to but not limited to a drug, test, procedure, treatment, device, or equipment that remains under study as its absolute risk is unestablished. Further study is required to determine the safety, effectiveness, toxicity, maximum tolerated dose, and efficacy of the EIS. It is generally not the standard therapy, therefore, not accepted by the professional medical community.

**Generally Accepted Standards of Medical Practice:** Standards that are based on credible scientific data, are published in peer-reviewed medical/scientific literature, are recognized by the relevant medical community, and align with physician specialty society recommendations and views of physicians practicing in the relevant clinical areas.

**Medically Necessary:** A service is "medically necessary" if:

- (1) it is reasonably calculated to prevent, diagnose, prevent the worsening of, alleviate, correct, or cure conditions in the member that endanger life, cause suffering or pain, cause physical deformity or malfunction, threaten to cause or to aggravate a handicap, or result in illness or infirmity; **and**
- (2) There is no other medical service or site of service, comparable in effect, available, and suitable for the member requesting the service, that is more conservative or less costly. Services that are less costly or more conservative include, but are not limited to, health care reasonably known by the provider, or identified by CCA pursuant to a prior authorization request, to be available to the member through the requesting provider or from another provider who is available to treat the member.

**Not Medically Necessary:** A healthcare service or product is considered not medically necessary when it is provided primarily for the convenience of the patient, physician, or other healthcare provider, and is more costly than an alternative service or sequence of services that may produce equivalent therapeutic or diagnostic effect in the diagnosis or treatment of the member's specific illness or disease. These healthcare service or products may be in accordance with generally accepted standards of medical practice and/or be clinically appropriate.

### DECISION GUIDELINES:

## Experimental & Investigational Services Medical Necessity Guideline

Commonwealth Care Alliance will not cover services, procedures, and/or supplies that are considered experimental, investigational, or unproven AND *not medically necessary* according to the following criteria:

- The service, procedure, or supply does not have final and/or unrestricted market approval from the FDA or from any other governmental regulatory body,
- Further study is required to determine the safety, efficacy, toxicity, or maximum tolerated dose for the service, procedure, or supply,
- There is insufficient authoritative evidence to allow for the evaluation of the therapeutic value of the service, procedure, or supply,
- There is insufficient authoritative evidence to permit the evaluation of *net health outcomes*,
- There is insufficient authoritative evidence that the service, procedure, or supply has a beneficial effect on health outcomes or is as beneficial as other alternative interventions or therapies, when used in a non-investigational setting,
- The service, procedure, or supply is not as beneficial as established alternative interventions or therapies, AND
- The service, procedure, or supply is not in accordance with *generally accepted standards of medical practice* or not generally accepted by in the professional medical community as safe and effective in the setting and condition for which it is used.

Commonwealth Care Alliance may cover services, procedures, and/or supplies that are considered experimental, investigational, or unproven when they meet the following criteria:

- The service, procedure, or supply request is evaluated by a CCA medical director,
- The service, procedure, or supply is determined to be *medically necessary* in accordance with the definition, regulatory and professional standards, and authoritative evidence,
- The medical necessity for the service, procedure, or supply is substantiated by:
  - Documentation to support that the service, procedure, or supply is medically necessary, AND
  - Complete copies (in full-text) of supporting peer-reviewed literature to indicate that the service, procedure, or supply is,
    - Safe and efficacious,
    - Generally accepted by the professional medical community,
    - Regarded or accepted as a comparable treatment for the member's underlying disease, AND
    - The most conservative or least costly alternative

OR

- Documentation that indicates that the service, procedure, or supply is:
  - The best treatment choice for the member due to their specific unique clinical circumstances,
  - Standard therapies have been tried and not been effective OR have been determined to not be medically appropriate,
  - There is reason to believe that the intervention requested will be successful when other treatments have failed.
- Complete copies (in full-text) of supporting peer-reviewed literature to indicate that the service, procedure, or supply is safe and efficacious.

The hierarchy of authoritative evidence that will be used to determine whether the service, procedure, or supply is safe and efficacious, generally accepted by the professional medical community, and regarded or accepted as a comparable treatment for the member's underlying disease, is:



## Experimental & Investigational Services Medical Necessity Guideline

- Published formal technology assessments and/or high-quality meta-analyses,
- Well-designed randomized studies published in credible, peer-reviewed literature,
- High quality case-control or cohort studies,
- Historical control studies, case reports, and/or case series,
- Reports of expert opinion from national professional medical societies or national medical policy organizations

### LIMITATIONS/EXCLUSIONS:

Commonwealth Care Alliance limits coverage to EIS services, procedures, or supplies wherein medical necessity has been determined, safety and efficacy has been established, and therapeutic benefit is comparable with standard treatment, evidenced by authoritative evidence. Reports, articles or statements from providers that contain only abstracts, anecdotal evidence, or personal professional opinions is not considered authoritative evidence.

Commonwealth Care Alliance will not cover the following EIS services, procedures, or supplies in the following list of procedure and/or diagnosis codes below. Information related to the list include:

- The following CPT/HCPCS procedure codes are considered as EIS and are generally not covered,
- The list is intended to be used as a reference and for informational purposes,
- When it states, there is “no specific code available” this indicates that it is an “unlisted code” or “miscellaneous code,”
- When it states, “EIU (experimental, investigational, or unproven)” in the third column of the list, non-coverage is implied, AND
  - Note: Codes of related therapy for similar conditions may be non-covered as an EIU
- The list is not all inclusive and may change as emerging evidence becomes available.

### AUTHORIZATION:

Medical Necessity Guidelines are published to provide a better understanding of the basis upon which coverage decisions are made. CCA makes coverage decisions on a case-by-case basis considering the individual member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the servicearea who are medical experts in the appropriate field, review of FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions. If at any time a CMS Local or National Coverage Determination (LCD or NCD) is published that conflicts with the criteria set forth herein, the NCD or LCD criteria shall supersede these criteria.



## Experimental & Investigational Services Medical Necessity Guideline

Code	Description	Details	Last Review Date
19105	Ablation, cryosurgical, of fibroadenoma, including ultrasound guidance, each fibroedenoma	EIU	2/21/2023
20985	Computer-assisted surgical navigational procedure for musculoskeletal procedures; image-less (MAKO Surgical Corp® (Stryker), RIO® Robotic Arm)	EIU	2/21/2023
22505	Manipulation Procedures on the Spine (Vertebral Column)	EIU	10/12/2023
22526	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level (IDET)	EIU	2/21/2023
22527	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; one or more additional levels (IDET)	EIU	2/21/2023
22586	Arthrodesis, pre-sacral interbody technique, including disc space preparation, discectomy, with posterior instrumentation, with image guidance, includes bone graft when performed, L5-S1 interspace	EIU	2/21/2023
22857	Total disc arthroplasty (artificial disc), anterior approach, including diskectomy to prepare interspace (other than decompression); single interspace, lumbar	EIU	2/21/2023
22868	Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; second level (List separately in addition to code for primary procedure)	EIU	2/21/2023
33274	Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed	EIU	2/21/2023
33275	Transcatheter removal of permanent leadless pacemaker, right ventricular	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

<b>33548</b>	Surgical ventricular restoration procedure, includes prosthetic patch, when performed (e.g., ventricular remodeling, SVR, SAVER, Dor procedures)	EIU	2/21/2023
<b>36473</b>	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechanochemical; first vein treated (e.g. "Clarivein")	EIU	2/21/2023
<b>36474</b>	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechanochemical; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure) (e.g. "Clarivein")	EIU	2/21/2023
<b>37241</b>	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; venous, other than hemorrhage (eg, congenital or acquired venous malformations, venous and capillary hemangiomas, varices, varicoceles){e.g., Percutaneous Transcatheter Coil Embolization for Pelvic Congestion Syndrome}	EIU	2/21/2023
<b>37790</b>	Penile venous occlusive procedure	EIU	2/21/2023
<b>41512</b>	Tongue base suspension, permanent suture technique	EIU	2/21/2023
<b>43206</b>	Esophagoscopy, rigid or flexible, with optical endomicroscopy	EIU	2/21/2023
<b>43252</b>	Upper gastrointestinal endoscopy including esophagus, stomach, and either the duodenum and/or jejunum as appropriate, with optical endomicroscopy	EIU	2/21/2023
<b>43257</b>	Upper Gastrointestinal Endoscopy with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease, (e.g., Stretta procedure, the Bard® EndoCinch™ Suturing System, Plicator™ and Enteryx™ )	EIU	2/21/2023
<b>43497</b>	Lower esophageal myotomy, transoral (ie, peroral endoscopic myotomy [POEM])	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

<b>53451</b>	Periurethral transperineal adjustable balloon continence device; bilateral insertion, including cystourethroscopy and imaging guidance (ProAct (Uromedica))	EIU	2/21/2023
<b>53452</b>	Periurethral transperineal adjustable balloon continence device; unilateral insertion, including cystourethroscopy and imaging guidance (ProAct (Uromedica))	EIU	2/21/2023
<b>53453</b>	Periurethral transperineal adjustable balloon continence device; removal, each balloon (ProAct (Uromedica))	EIU	2/21/2023
<b>53454</b>	Periurethral transperineal adjustable balloon continence device; percutaneous adjustment of balloon(s) fluid volume (ProAct (Uromedica))	EIU	2/21/2023
<b>53860</b>	Transurethral, radiofrequency micro-remodeling of the female bladder neck and proximal urethra for stress urinary incontinence	EIU	2/21/2023
<b>55880</b>	Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance	EIU	2/21/2023
<b>61736</b>	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; single trajectory for 1 simple lesion	EIU	2/21/2023
<b>61737</b>	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; multiple trajectories for multiple or complex lesion(s)	EIU	2/21/2023
<b>61885</b>	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array	EIU EXCEPT for ICD10:F32.0-F32.5, F33.0-F33.3, G20, G21.4, G24.1, G25.0- G25.2, G40.011- G40.019; G40.111-G40.119; G40.211- G40.219, G40.311- G40.319, G40.813, G40.814, G40.A11, G40.A19	5/9/2024
<b>61886</b>	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode arrays	EIU EXCEPT for ICD10:F32.0-F32.5, F33.0-F33.3, G20, G21.4, G24.1, G25.0- G25.2, G40.011- G40.019; G40.111- G40.119; G40.211- G40.219, G40.311- G40.319, G40.813, G40.814, G40.A11, G40.A19	5/9/2024



## Experimental & Investigational Services Medical Necessity Guideline

<b>62287</b>	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, any method utilizing needle-based technique to remove disc material under fluoroscopic imaging or other form of indirect visualization, with the use of an endoscope, with discography and/or epidural injection(s) at the treated level(s), when performed, single or multiple levels, lumbar	EIU	2/21/2023
<b>64505</b>	Injection, anesthetic agent; sphenopalatine ganglion	EIU	2/21/2023
<b>64553</b>	Percutaneous implantation of neurostimulator electrodes; cranial nerve	EIU	2/21/2023
<b>64561</b>	Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed	EIU when submitted with the following codes: M53.3, M54.16, M54.17, M54.18, M54.40, M54.41, M54.42, M54.50, M54.51, M54.59, M54.9	2/21/2023
<b>64590</b>	Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling	EIU for K59.00, R10.2, R33.9, N39.3, G62, G64, G90, 356.9, E10.43, K31.84, Z4542, M54.81, R51, G43, G44	6/2/2022
<b>64595</b>	Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver	EIU for K59.00, R10.2, R33.9, N39.3, G62, G64, G90, 356.9, E10.43, K31.84, Z4542, M54.81, R51, G43, G44	6/2/2022
<b>64640</b>	Destruction by neurolytic agent; other peripheral nerve or branch (when requested as iovera)	EIU for M17.0-M17.9	1/4/2023
<b>64624</b>	Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed (when requested as iovera)	EIU for M17.0-M17.9	1/4/2023
<b>64625</b>	Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (ie, fluoroscopy or computed tomography)	EIU	2/21/2023
<b>64628</b>	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral (Intaccept)	EIU	2/21/2023



## Experimental & Investigational Services Medical Necessity Guideline

<b>64629</b>	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral (List separately in addition to code for primary procedure) (Intaccept)	EIU	2/21/2023
<b>68841</b>	Insertion of drug-eluting implant, including punctal dilation when performed, into lacrimal canaliculus, each	EIU	2/21/2023
<b>69705</b>	Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); unilateral	EIU	2/21/2023
<b>69706</b>	Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); bilateral	EIU	2/21/2023
<b>76977</b>	Ultrasound bone density measurement and interpretation, peripheral site(s), any method	EIU	2/21/2023
<b>76982</b>	Ultrasound, elastography, first target lesion	EIU	2/21/2023
<b>76983</b>	Ultrasound, elastography, each additional target lesion (List separately in addition to code for primary procedure)	EIU	2/21/2023
<b>77089</b>	Trabecular bone score (TBS), structural condition of the bone microarchitecture; using dual Xray absorptiometry (DXA) or other imaging data on gray-scale variogram, calculation, with interpretation and report on fracture-risk	EIU	2/21/2023
<b>80145</b>	Adalimumab	EIU	2/21/2023
<b>80230</b>	Infliximab	EIU	2/21/2023
<b>80280</b>	Vedolizumab	EIU	2/21/2023
<b>81490</b>	Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score, (e.g., Vectra® DA)	EIU	2/21/2023
<b>81500</b>	Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score, (e.g., Risk of Ovarian Malignancy Algorithm (ROMA™))	EIU	2/21/2023
<b>81503</b>	Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin and prealbumin), utilizing serum, algorithm reported as a risk score (OVA1™, Vermillion, Inc.)	EIU	2/21/2023
<b>81506</b>	Endocrinology (type 2 diabetes), biochemical assays of seven analytes (glucose, HbA1c, insulin, hs-CRP, adiponectin, ferritin, interleukin 2-	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

	receptor alpha), utilizing serum or plasma, algorithm reporting a risk score, (e.g., PreDx™ Diabetes Risk Score)		
<b>81535</b>	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; first single drug or drug combination, (ChemoFx, Helomics)	EIU	2/21/2023
<b>81536</b>	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; each additional single drug or drug combination (List separately in addition to code for primary procedure), (ChemoFx, Helomics)	EIU	2/21/2023
<b>81538</b>	Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum, prognostic and predictive algorithm reported as good versus poor overall survival, (VeriStrat, Biodesix, Inc.)	EIU	2/21/2023
<b>81560</b>	Transplantation medicine (allograft rejection, pediatric liver and small bowel), measurement of donor and third-party-induced CD154+Tcytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score (Pleximmune test)	EIU	2/21/2023
<b>82777</b>	Galectin-3	EIU	2/21/2023
<b>83006</b>	Growth stimulation expressed gene 2 (ST2, Interleukin 1 receptor like-1)	EIU	2/21/2023
<b>83631</b>	Lactoferrin, fecal, quantitative	EIU	2/21/2023
<b>83987</b>	pH; exhaled breath condensate	EIU	2/21/2023
<b>84145</b>	Procalcitonin (PCT)	EIU	2/21/2023
<b>86152</b>	Cell enumeration using immunologic selection and identification in fluid specimen (e.g., circulating tumor cells in blood); (e.g., CellSearch Circulating Tumor Cell (CTC) Kit for monitoring Metastatic Breast Cancer)	EIU	2/21/2023
<b>86153</b>	Cell enumeration using immunologic selection and identification in fluid specimen (e.g., circulating tumor cells in blood); physician interpretation and report, when required, (e.g., CellSearch Circulating Tumor Cell (CTC) Kit for monitoring Metastatic Breast Cancer)	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

<b>86343</b>	Leukocyte histamine release test (LHR)	EIU	2/21/2023
<b>88375</b>	Optical endomicroscopic image(s), interpretation and report, realtime or referred, each endoscopic session	EIU	2/21/2023
<b>91113</b>	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), colon, with interpretation and report (Pillcam 2 (medtronic))	EIU	2/21/2023
<b>92145</b>	Corneal hysteresis determination, by air impulse stimulation, unilateral or bilateral, with interpretation and report	EIU	2/21/2023
<b>92512</b>	Nasal function studies	EIU	2/21/2023
<b>92548</b>	Computerized dynamic posturography	EIU	2/21/2023
<b>92549</b>	Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)	EIU	2/21/2023
<b>93264</b>	Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional	EIU	2/21/2023
<b>93278</b>	Signal-averaged electrocardiography (SAECG), with or without ECG	EIU	2/21/2023
<b>93356</b>	Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics (List separately in addition to codes for echocardiography imaging)	EIU	2/21/2023
<b>93702</b>	Bioimpedance spectroscopy (BIS), extracellular fluid analysis for lymphedema assessment(s)	EIU	2/21/2023
<b>93895</b>	Quantitative carotid intima media thickness and carotid atheroma evaluation, bilateral	EIU	2/21/2023
<b>95060</b>	Ophthalmic mucous membrane tests	EIU	2/21/2023
<b>95065</b>	Direct nasal mucous membrane test	EIU	2/21/2023
<b>95803</b>	Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording)	EIU	2/21/2023
<b>96904</b>	Whole body integumentary photography, for monitoring of high-risk patients with dysplastic	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

	nevus syndrome or a history of dysplastic nevi, or patients with a personal or familial history of melanoma (e.g., MelaFind®)		
<b>97610</b>	Low frequency, non-contact, nonthermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day	EIU	2/21/2023
<b>A2001</b>	InnovaMatrix AC, per sq cm	EIU	2/21/2023
<b>A2002</b>	Mirragen Advanced Wound Matrix, per sq cm	EIU	2/21/2023
<b>A2004</b>	XCelliStem, per sq cm	EIU	2/21/2023
<b>A2005</b>	Microlyte Matrix, per sq cm	EIU	2/21/2023
<b>A2006</b>	NovoSorb SynPath dermal matrix, per sq cm	EIU	2/21/2023
<b>A2007</b>	Restrata, per sq cm	EIU	2/21/2023
<b>A2008</b>	TheraGenesis, per sq cm	EIU	2/21/2023
<b>A2009</b>	Symphony, per sq cm	EIU	2/21/2023
<b>A2010</b>	Apis, per sq cm	EIU	2/21/2023
<b>A2011</b>	Supra SDRM, per sq cm	EIU	2/21/2023
<b>A2012</b>	SUPRATHEL, per sq cm	EIU	2/21/2023
<b>A9272</b>	Wound suction, disposable, includes dressing, all accessories and components, any type, each, (e.g., PICO™ Single Use Negative Pressure Wound Therapy System) (NPWT)	EIU	2/21/2023
<b>A9291</b>	Prescription digital cognitive and/or behavioral therapy, FDAcleared, per course of treatment	EIU	2/21/2023
<b>C1818</b>	Integrated Keratoprosthesis	EIU	6/2/2022
<b>C1821</b>	Interspinous process distraction device (implantable)	EIU	2/21/2023
<b>C1823</b>	Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads	EIU	2/21/2023
<b>C1824</b>	Generator, cardiac contractility modulation (implantable)	EIU	2/21/2023
<b>C1825</b>	Generator, neurostimulator (implantable), non-rechargeable with carotid sinus baroreceptor stimulation lead(s)	EIU	2/21/2023
<b>C2624</b>	Implantable wireless pulmonary artery pressure sensor with delivery catheter, including all system components (e.g., CardioMEMSTM HF System)	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

<b>C9751</b>	Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-D rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (e.g., aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)	EIU	2/21/2023
<b>C9755</b>	Creation of arteriovenous fistula, percutaneous using magnetic-guided arterial and venous catheters and radiofrequency energy, including flow-directing procedures (e.g., vascular coil embolization with radiologic supervision and interpretation, when performed) and fistulogram(s), angiography, venography, and/or ultrasound, with radiologic supervision and interpretation, when performed	EIU	2/21/2023
<b>C9757</b>	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and excision of herniated intervertebral disc, and repair of annular defect with implantation of bone anchored annular closure device, including annular defect measurement, alignment and sizing assessment, and image guidance; 1 interspace, lumbar	EIU	2/21/2023
<b>C9758</b>	Blinded procedure for NYHA Class III/IV heart failure; transcatheter implantation of interatrial shunt or placebo control, including right heart catheterization, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study	EIU	2/21/2023
<b>C9760</b>	Nonrandomized, nonblinded procedure for NYHA Class II, III, IV heart failure, transcatheter implantation of interatrial shunt or placebo control, including right and left heart catheterization, transeptal puncture, transesophageal echocardiography	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

	(TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study		
<b>C9771</b>	Nasal/sinus endoscopy, cryoablation nasal tissue(s) and/or nerve(s), unilateral or bilateral	EIU	2/21/2023
<b>C9782</b>	Blinded procedure for New York Heart Association (NYHA) Class II or III heart failure, or Canadian Cardiovascular Society (CCS) Class III or IV chronic refractory angina; transcatheter intramyocardial transplantation of autologous bone marrow cells (e.g., mononuclear) or placebo control, autologous bone marrow harvesting and preparation for transplantation, left heart catheterization including ventriculography, all laboratory services, and all imaging with or without guidance (e.g., transthoracic echocardiography, ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study	EIU	2/21/2023
<b>C9783</b>	Blinded procedure for transcatheter implantation of coronary sinus reduction device or placebo control, including vascular access and closure, right heart catheterization, venous and coronary sinus angiography, imaging guidance and supervision and interpretation when performed in an approved investigational device exemption (IDE) study	EIU	2/21/2023
<b>E0218</b>	Fluid circulating cold pad with pump, any type	EIU	7/13/2023
<b>E0221</b>	Infrared heating pad system	EIU	2/21/2023
<b>E0236</b>	Pump for water circulating pad	EIU	2/21/2023
<b>E0746</b>	Electromyography (EMG), biofeedback device (when used for SPEAC System)	EIU	2/21/2023
<b>E0749</b>	Osteogenesis stimulator, electrical, surgically implanted	EIU	2/21/2023
<b>E0761</b>	Nonthermal pulsed high frequency radiowaves, high peak power electromagnetic energy treatment device	EIU	2/21/2023
<b>E0762</b>	Transcutaneous electrical joint stimulation device system, includes all accessories	EIU	2/21/2023
<b>E0765</b>	FDA approved nerve stimulator, with replaceable batteries, for treatment of nausea and vomiting	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

<b>E0769</b>	Electrical stimulation or electromagnetic wound treatment device, not otherwise classified	EIU	2/21/2023
<b>E0770</b>	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified	EIU	2/21/2023
<b>E2001</b>	Suction pump, home model, portable or stationary, electric, any type, for use with external urine management system (when requested as PureWick)	EIU	1/1/24
<b>E2120</b>	Pulse generator system for tympanic treatment of inner ear endolymphatic fluid	EIU	2/21/2023
<b>G0255</b>	Current perception threshold/sensory nerve conduction test, (SNCT) per limb, any nerve	EIU	2/21/2023
<b>G0282</b>	Electrical stimulation, (unattended), to one or more areas, for wound care	EIU	2/21/2023
<b>G0295</b>	Electromagnetic therapy, to one or more areas, for wound care other than described in G0329 or for other uses	EIU	2/21/2023
<b>G0327</b>	Colorectal cancer screening, bloodbased biomarker	EIU	2/21/2023
<b>G0428</b>	Collagen meniscus implant procedure for filling meniscal defects (e.g., CMI, collagen scaffold, Menaflex)	EIU	2/21/2023
<b>J2001</b> <b>J3490</b> <b>96365</b> <b>96366</b> <b>96374</b>	IV Infusions of anesthetics (e.g., ketamine or lidocaine) for the management of: (1) Chronic pain (including but not limited to chronic neuropathic pain, chronic daily headache, and fibromyalgia) Behavioral health conditions (including but not limited to depression, bipolar disorder, post-traumatic stress disorder, autism spectrum disorder, and obsessive-compulsive disorder)	EIU	6/2/2022
<b>K1007</b>	Powered exoskeletons for ambulation in patients with lower limb disabilities.	EIU	6/2/2022
<b>K1016</b>	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve	EIU	2/21/2023
<b>K1017</b>	Monthly supplies for use of device coded at K1016	EIU	2/21/2023
<b>K1018</b>	External upper limb tremor stimulator of the peripheral nerves of the wrist	EIU	2/21/2023
<b>K1019</b>	Replacement supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist	EIU	2/21/2023



## Experimental & Investigational Services Medical Necessity Guideline

<b>K1020</b>	Noninvasive vagus nerve stimulator	EIU	2/21/2023
<b>K1021</b>	Exsufflation belt, includes all supplies and accessories	EIU	2/21/2023
<b>K1023</b>	Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm	EIU	2/21/2023
<b>K1024</b>	Nonpneumatic compression controller with sequential calibrated gradient pressure	EIU	2/21/2023
<b>K1025</b>	Nonpneumatic sequential compression garment, full arm	EIU	2/21/2023
<b>K1027</b>	Oral device/appliance used to reduce upper airway collapsibility, without fixed mechanical hinge, custom fabricated, includes fitting and adjustment	EIU	2/21/2023
<b>K1028</b>	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle for the reduction of snoring and obstructive sleep apnea, controlled by phone application	EIU	2/21/2023
<b>K1029</b>	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply	EIU	2/21/2023
<b>K1030</b>	External recharging system for battery (internal) for use with implanted cardiac contractility modulation generator, replacement only	EIU	2/21/2023
<b>L2006</b>	Knee-ankle-foot (KAF) device, any material, single or double upright, swing and/or stance phase microprocessor control with adjustability, includes all components (e.g., sensors, batteries, charger), any type activation, with or without ankle joint(s), custom fabricated	EIU	2/21/2023
<b>L5969</b>	Addition, endoskeletal ankle-foot or ankle system, power assist, includes any type motor(s)	EIU	2/21/2023
<b>L6880</b>	Electric Hand, Switch Or Myoelectric Controlled, Independently Articulating Digits, Any Grasp Pattern Or Combination Of Grasp Patterns, Includes Motor(s)	EIU	6/2/2022
<b>L8605</b>	Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, anal canal, 1 ml, includes shipping and necessary supplies, e.g., SOLESTA® (hyaluronicacid/dextranomer)	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

<b>L8607</b>	Injectable bulking agent for vocal cord medialization, 0.1 ml, includes shipping and necessary supplies	EIU	2/21/2023
<b>L8608</b>	Miscellaneous external component, supply or accessory for use with the Argus II Retinal Prosthesis System	EIU	2/21/2023
<b>L8701</b>	Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated.	EIU	6/2/2022
<b>L8702</b>	Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated.	EIU	6/2/2022
<b>M0076</b>	Prolotherapy	EIU	2/21/2023
<b>M0300</b>	IV chelation therapy (chemical endarterectomy)	EIU	2/21/2023
<b>S1091</b>	Stent, noncoronary, temporary, with delivery system (Propel)	EIU	2/21/2023
<b>S2080</b>	Laser-assisted uvulopalatoplasty (LAUP)	EIU	2/21/2023
<b>S2348</b>	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar	EIU	2/21/2023
<b>S3900</b>	Surface electromyography (EMG)	EIU	2/21/2023
<b>S8080</b>	Scintimammography (radioimmunosintigraphy of the breast), unilateral, including supply of radiopharmaceutical	EIU	2/21/2023
<b>S8092</b>	Electron beam computed tomography (also known as ultrafast CT, Cine CT)	EIU	2/21/2023
<b>S8930</b>	Electrical stimulation of auricular acupuncture points; each 15 minutes of personal one-on-one contact with patient (e.g., PSTIM™)	EIU	2/21/2023
<b>S9024</b>	Paranasal sinus ultrasound	EIU	2/21/2023
<b>S9090</b>	Vertebral axial decompression, per session	EIU	2/21/2023
<b>Q4134</b>	hMatrix, per sq cm	EIU	2/21/2023
<b>Q4135</b>	Mediskin, per sq cm	EIU	2/21/2023
<b>Q4136</b>	E-Z Derm, per sq cm	EIU	2/21/2023
<b>Q4140</b>	BioDFence® and BioDFence® G3 human amniotic allograft products	EIU	2/21/2023
<b>Q4148</b>	NEOX 1k, per square centimeter	EIU	2/21/2023



## Experimental & Investigational Services Medical Necessity Guideline

Q4150	Allowrap DS or dry, per sq cm	EIU	2/21/2023
Q4152	Dermapure, per sq cm	EIU	2/21/2023
Q4153	Dermavest, per sq cm	EIU	2/21/2023
Q4154	Biovance, per sq cm	EIU	2/21/2023
Q4155	Neoxflo or clarixflo 1 mg	EIU	2/21/2023
Q4156	Neox 100, per sq cm	EIU	2/21/2023
Q4157	Revitalon, per sq cm	EIU	2/21/2023
Q4158	Kerecis Omega3, per sq cm	EIU	2/21/2023
Q4159	Affinity, per sq cm	EIU	2/21/2023
Q4160	Nushield, per square centimeter	EIU	2/21/2023
Q4166	Cytal, per square centimeter	EIU	2/21/2023
Q4167	Truskin, per square centimeter	EIU	2/21/2023
Q4169	Artacent wound, per square centimeter	EIU	2/21/2023
Q4170	Cygnus, per square centimeter	EIU	2/21/2023
Q4171	Interfyl, 1 mg	EIU	2/21/2023
Q4173	Palingen or palingen xplus, per square centimeter	EIU	2/21/2023
Q4174	Palingen or promatrx, 0.36 mg per 0.25 cc	EIU	2/21/2023
Q4175	Miroderm, per square centimeter	EIU	2/21/2023
Q4176	NeoPatch, per sq cm	EIU	2/21/2023
Q4177	FlowerAmnioFlo, 0.1 cc	EIU	2/21/2023
Q4178	FlowerAmnioPatch, per sq cm	EIU	2/21/2023
Q4179	FlowerDerm, per sq cm	EIU	2/21/2023
Q4180	Revita, per sq cm	EIU	2/21/2023
Q4181	Amnio Wound, per sq cm	EIU	2/21/2023
Q4183	Surgigraft, per sq cm	EIU	2/21/2023
Q4184	Cellesta, per sq cm	EIU	2/21/2023
Q4185	Cellesta Flowable Amnion (25 mg per cc); per 0.5 cc	EIU	2/21/2023
Q4188	AmnioArmor, per sq cm	EIU	2/21/2023
Q4189	Artacent AC, per sq cm	EIU	2/21/2023
Q4191	Restorigin, per sq cm	EIU	2/21/2023
Q4192	Restorigin, 1 cc	EIU	2/21/2023
Q4193	Coll-e-Derm, per sq cm	EIU	2/21/2023
Q4194	Novachor, per sq cm	EIU	2/21/2023
Q4195	PuraPly, per sq cm	EIU	2/21/2023
Q4196	PuraPly AM, per sq cm	EIU	2/21/2023
Q4197	PuraPly XT, per sq cm	EIU	2/21/2023
Q4198	Genesis Amniotic Membrane, per sq cm	EIU	2/21/2023
Q4200	SkinTE, per sq cm	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

Q4201	Matrion, per sq cm	EIU	2/21/2023
Q4202	Keroxx (2.5 g/cc), 1 cc	EIU	2/21/2023
Q4203	Derma-Gide, per sq cm	EIU	2/21/2023
Q4204	XWRAP, per sq cm	EIU	2/21/2023
Q4205	Membrane Graft or Membrane Wrap, per sq cm	EIU	2/21/2023
Q4206	Fluid Flow or Fluid GF, 1 cc	EIU	2/21/2023
Q4208	Novafix, per sq cm	EIU	2/21/2023
Q4209	SurGraft, per sq cm	EIU	2/21/2023
Q4210	Axolotl Graft or Axolotl DualGraft, per sq cm	EIU	2/21/2023
Q4211	Amnion Bio or AxoBioMembrane, per sq cm	EIU	2/21/2023
Q4212	AlloGen, per cc	EIU	2/21/2023
Q4213	Ascent, 0.5 mg	EIU	2/21/2023
Q4214	Cellesta Cord, per sq cm	EIU	2/21/2023
Q4215	Axolotl Ambient or Axolotl Cryo, 0.1 mg	EIU	2/21/2023
Q4216	Artacent Cord, per sq cm	EIU	2/21/2023
Q4217	WoundFix, BioWound, WoundFix Plus, BioWound Plus, WoundFix Xplus or BioWound Xplus, per sq cm	EIU	2/21/2023
Q4218	SurgiCORD, per sq cm	EIU	2/21/2023
Q4219	SurgiGRAFT-DUAL, per sq cm	EIU	2/21/2023
Q4220	BellaCell HD or Surederm, per sq cm	EIU	2/21/2023
Q4221	Amnio Wrap2, per sq cm	EIU	2/21/2023
Q4222	ProgenaMatrix, per sq cm	EIU	2/21/2023
Q4224	Human Health Factor 10 Amniotic Patch (HHF10-P), per sq cm	EIU	2/21/2023
Q4225	AmnioBind, per sq cm	EIU	2/21/2023
Q4226	MyOwn Skin, includes harvesting and preparation procedures, per sq cm	EIU	2/21/2023
Q4227	AmnioCore™, per sq cm	EIU	2/21/2023
Q4229	Cogenex Amniotic Membrane, per sq cm	EIU	2/21/2023
Q4230	Cogenex Flowable Amnion, per 0.5 cc	EIU	2/21/2023
Q4231	Corplex P, per cc	EIU	2/21/2023
Q4232	Corplex, per sq cm	EIU	2/21/2023
Q4233	SurFactor or NuDyn, per 0.5 cc	EIU	2/21/2023
Q4234	XCellerate, per sq cm	EIU	2/21/2023
Q4235	AMNIOREPAIR or AltiPly, per sq cm	EIU	2/21/2023
Q4237	Cryo-Cord, per sq cm	EIU	2/21/2023
Q4238	Derm-Maxx, per sq cm	EIU	2/21/2023
Q4239	Amnio-Maxx or Amnio-Maxx Lite, per sq cm	EIU	2/21/2023
Q4240	CoreCyte, for topical use only, per 0.5 cc	EIU	2/21/2023
Q4241	PolyCyte, for topical use only, per 0.5 cc	EIU	2/21/2023
Q4242	AmnioCyte Plus, per 0.5 cc	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

<b>Q4244</b>	Procenta, per 200 mg	EIU	2/21/2023
<b>Q4245</b>	AmnioText, per cc	EIU	2/21/2023
<b>Q4246</b>	CoreText or ProText, per cc	EIU	2/21/2023
<b>Q4247</b>	Amniotext patch, per sq cm	EIU	2/21/2023
<b>Q4248</b>	Dermacyte Amniotic Membrane Allograft, per sq cm	EIU	2/21/2023
<b>Q4249</b>	AMNIPLY, for topical use only, per sq cm	EIU	2/21/2023
<b>Q4250</b>	AmnioAmp-MP, per sq cm	EIU	2/21/2023
<b>Q4254</b>	Novafix DL, per sq cm	EIU	2/21/2023
<b>Q4255</b>	REGUaRD, for topical use only, per sq cm	EIU	2/21/2023
<b>Q4256</b>	MLG-Complete, per sq cm	EIU	2/21/2023
<b>Q4257</b>	Relese, per sq cm	EIU	2/21/2023
<b>Q4258</b>	Enverse, per sq cm	EIU	2/21/2023
<b>Q4260</b>	Signature APatch, per sq cm	EIU	2/21/2023
<b>Q4261</b>	TAG, per sq cm	EIU	2/21/2023
<b>0042T</b>	Cerebral perfusion analysis using computed tomography with contrast administration, including post-processing of parametric maps with determination of cerebral blood flow, cerebral blood volume, and mean transit time	EIU	2/21/2023
<b>0054T</b>	Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance based on fluoroscopic images (List separately in addition to code for primary procedure)	EIU	2/21/2023
<b>0055T</b>	Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance based on CT/MRI images (List separately in addition to code for primary procedure)	EIU	2/21/2023
<b>0071T</b>	Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume less than 200 cc of tissue	EIU	2/21/2023
<b>0072T</b>	Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume greater or equal to 200 cc of tissue	EIU	2/21/2023
<b>0075T</b>	Transcatheter placement of extracranial vertebral or intrathoracic carotid artery stent(s),	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

	including radiologic supervision and interpretation, percutaneous; initial vessel		
<b>0076T</b>	Transcatheter placement of extracranial vertebral or intrathoracic carotid artery stent(s), including radiologic supervision and interpretation, percutaneous; each additional vessel	EIU	2/21/2023
<b>0100T</b>	Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy	EIU	2/21/2023
<b>0101T</b>	Extracorporeal shock wave involving musculoskeletal system, not otherwise specified, high energy	EIU	2/21/2023
<b>0102T</b>	Extracorporeal shock wave, high energy, performed by a physician, requiring anesthesia other than local, involving lateral humeral epicondyle	EIU	2/21/2023
<b>0106T</b>	Quantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation	EIU	2/21/2023
<b>0107T</b>	Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to assess large diameter fiber sensation	EIU	2/21/2023
<b>0108T</b>	Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia	EIU	2/21/2023
<b>0109T</b>	Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia	EIU	2/21/2023
<b>0110T</b>	Quantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensation	EIU	2/21/2023
<b>0164T</b>	Removal of total disc arthroplasty, (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)	EIU	2/21/2023
<b>0165T</b>	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, lumbar (List	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

	separately in addition to code for primary procedure)		
<b>0174T</b>	Computer-aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed concurrent with primary interpretation	EIU	2/21/2023
<b>0175T</b>	Computer-aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed remote from primary interpretation	EIU	2/21/2023
<b>0198T</b>	Measurement of ocular blood flow by repetitive intraocular pressure sampling, with interpretation and report	EIU	2/21/2023
<b>0200T</b>	Percutaneous sacral augmentation (sacroplasty), unilateral injection(s), including the use of a balloon or mechanical device, when used, 1 or more needles, includes imaging guidance and bone biopsy, when performed	EIU	2/21/2023
<b>0201T</b>	Percutaneous sacral augmentation (sacroplasty), bilateral injections, including the use of a balloon or mechanical device, when used, 2 or more needles, includes imaging guidance and bone biopsy, when performed	EIU	2/21/2023
<b>0202T</b>	Posterior vertebral joint(s) arthroplasty (e.g., facet joint[s] replacement) including facetectomy, laminectomy, foraminotomy and vertebral column fixation, with or without injection of bone cement, including fluoroscopy, single level, lumbar spine	EIU	2/21/2023
<b>0207T</b>	Evacuation of Meibomian glands, automated, using heat and intermittent pressure, unilateral	EIU	2/21/2023
<b>0208T</b>	Pure tone audiometry (threshold), automated (includes use of computer-assisted device); air only	EIU	2/21/2023
<b>0209T</b>	Pure tone audiometry (threshold), automated (includes use of computer-assisted device); air and bone	EIU	2/21/2023



## Experimental & Investigational Services Medical Necessity Guideline

<b>0210T</b>	Speech audiometry threshold, automated (includes use of computer-assisted device);	EIU	2/21/2023
<b>0211T</b>	Speech audiometry threshold, automated (includes use of computer-assisted device); with speech recognition	EIU	2/21/2023
<b>0212T</b>	Comprehensive audiometry threshold evaluation and speech recognition (0209T, 0211T combined), automated (includes use of computer-assisted device)	EIU	2/21/2023
<b>0232T</b>	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed	EIU	2/21/2023
<b>0263T</b>	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure including unilateral or bilateral bone marrow harvest	EIU	2/21/2023
<b>0264T</b>	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure excluding bone marrow harvest	EIU	2/21/2023
<b>0265T</b>	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; unilateral or bilateral bone marrow harvest only for intramuscular autolog	EIU	2/21/2023
<b>0266T</b>	Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intraoperative interrogation, programming, and repositioning, when performed)	EIU	2/21/2023
<b>0267T</b>	Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)	EIU	2/21/2023
<b>0268T</b>	Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, pulse generator	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

	only (includes intraoperative interrogation, programming, and repositioning, when performed)		
<b>0269T</b>	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)	EIU	2/21/2023
<b>0270T</b>	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)	EIU	2/21/2023
<b>0271T</b>	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)	EIU	2/21/2023
<b>0272T</b>	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (e.g., battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day);	EIU	2/21/2023
<b>0273T</b>	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (e.g., battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day); with programming	EIU	2/21/2023
<b>0275T</b>	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

	foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), with or without the use of an endoscope, single or multiple levels, unilateral or bilateral; lumbar		
<b>0278T</b>	Transcutaneous electrical modulation pain reprocessing (e.g., scrambler therapy), each treatment session (includes placement of electrodes)	EIU	2/21/2023
<b>0330T</b>	Tear film imaging, unilateral or bilateral, with interpretation and report	EIU	2/21/2023
<b>0331T</b>	Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment;	EIU	2/21/2023
<b>0332T</b>	Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment, with tomographic SPECT	EIU	2/21/2023
<b>0335T</b>	Insertion of sinus tarsi implant	EIU	2/21/2023
<b>0338T</b>	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral	EIU	2/21/2023
<b>0339T</b>	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral	EIU	2/21/2023
<b>0342T</b>	Therapeutic apheresis with selective HDL delipidation and plasma reinfusion	EIU	2/21/2023
<b>0351T</b>	Optical coherence tomography of breast or axillary lymph node, excised tissue, each specimen; real time intraoperative	EIU	2/21/2023
<b>0352T</b>	Optical coherence tomography of breast or axillary lymph node, excised tissue, each specimen; interpretation and report, real time or referred	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

<b>0353T</b>	Optical coherence tomography of breast, surgical cavity; real time intraoperative	EIU	2/21/2023
<b>0354T</b>	Optical coherence tomography of breast, surgical cavity; interpretation and report, real time or referred	EIU	2/21/2023
<b>0358T</b>	Bioelectrical impedance analysis whole body composition assessment, supine position, with interpretation and report	EIU	2/21/2023
<b>0394T</b>	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed	EIU	2/21/2023
<b>0395T</b>	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed	EIU	2/21/2023
<b>0397T</b>	Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy (List separately in addition to code for primary procedure)	EIU	2/21/2023
<b>0398T</b>	Magnetic resonance image guided high intensity focused ultrasound (MRgFUS), stereotactic ablation lesion, intracranial for movement disorder including stereotactic navigation and frame placement when performed	EIU	2/21/2023
<b>0408T</b>	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator with transvenous electrodes	EIU	2/21/2023
<b>0409T</b>	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only	EIU	2/21/2023
<b>0410T</b>	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; atrial electrode only	EIU	2/21/2023
<b>0411T</b>	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

	programming of sensing and therapeutic parameters; ventricular electrode only		
<b>0412T</b>	Removal of permanent cardiac contractility modulation system; pulse generator only	EIU	2/21/2023
<b>0413T</b>	Removal of permanent cardiac contractility modulation system; transvenous electrode (atrial or ventricular)	EIU	2/21/2023
<b>0414T</b>	Removal and replacement of permanent cardiac contractility modulation system pulse generator only	EIU	2/21/2023
<b>0415T</b>	Repositioning of previously implanted cardiac contractility modulation transvenous electrode, (atrial or ventricular lead)	EIU	2/21/2023
<b>0416T</b>	Relocation of skin pocket for implanted cardiac contractility modulation pulse generator	EIU	2/21/2023
<b>0417T</b>	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation system	EIU	2/21/2023
<b>0418T</b>	Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter; implantable cardiac contractility modulation system	EIU	2/21/2023
<b>0424T</b>	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead, sensing lead, implantable pulse generator)	EIU	2/21/2023
<b>0425T</b>	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; sensing lead only	EIU	2/21/2023
<b>0426T</b>	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; stimulation lead only	EIU	2/21/2023
<b>0427T</b>	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; pulse generator only	EIU	2/21/2023
<b>0428T</b>	Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

<b>0429T</b>	Removal of neurostimulator system for treatment of central sleep apnea; sensing lead only	EIU	2/21/2023
<b>0430T</b>	Removal of neurostimulator system for treatment of central sleep apnea; stimulation lead only	EIU	2/21/2023
<b>0431T</b>	Removal and replacement of neurostimulator system for treatment of central sleep apnea, pulse generator only	EIU	2/21/2023
<b>0432T</b>	Repositioning of neurostimulator system for treatment of central sleep apnea; stimulation lead only	EIU	2/21/2023
<b>0433T</b>	Repositioning of neurostimulator system for treatment of central sleep apnea; sensing lead only	EIU	2/21/2023
<b>0434T</b>	Interrogation device evaluation implanted neurostimulator pulse generator system for central sleep apnea	EIU	2/21/2023
<b>0435T</b>	Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; single session	EIU	2/21/2023
<b>0436T</b>	Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; during sleep study	EIU	2/21/2023
<b>0440T</b>	Ablation, percutaneous, cryoablation, includes imaging guidance; upper extremity distal/peripheral nerve	EIU	2/21/2023
<b>0441T</b>	Ablation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve	EIU	2/21/2023
<b>0442T</b>	Ablation, percutaneous, cryoablation, includes imaging guidance; nerve plexus or other truncal nerve (eg, brachial plexus, pudendal nerve)	EIU	2/21/2023
<b>0444T</b>	Initial placement of a drug-eluting ocular insert under one or more eyelids, including fitting, training, and insertion, unilateral or bilateral	EIU	2/21/2023
<b>0445T</b>	Subsequent placement of a drugeluting ocular insert under one or more eyelids, including re-training, and removal of existing insert, unilateral or bilateral	EIU	2/21/2023
<b>0464T</b>	Visual evoked potential, testing for glaucoma, with interpretation and report	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

<b>0469T</b>	Retinal polarization scan, ocular screening with on-site automated results, bilateral	EIU	2/21/2023
<b>0472T</b>	Device evaluation, interrogation, and initial programming of intraocular retinal electrode array (eg, retinal prosthesis), in person, with iterative adjustment of the implantable device to test functionality, select optimal permanent programmed values with analysis, including visual training, with review and report by a qualified health care professional	EIU	2/21/2023
<b>0473T</b>	Device evaluation and interrogation of intra-ocular retinal electrode array (eg, retinal prosthesis), in person, including reprogramming and visual training, when performed, with review and report by a qualified health care professional	EIU	2/21/2023
<b>0474T</b>	Insertion of anterior segment aqueous drainage device, with creation of intraocular reservoir, internal approach, into the supraciliary space (CyPass MicroStent)	EIU	2/21/2023
<b>0485T</b>	Optical coherence tomography (OCT) of middle ear, with interpretation and report; unilateral	EIU	2/21/2023
<b>0486T</b>	Optical coherence tomography (OCT) of middle ear, with interpretation and report; bilateral	EIU	2/21/2023
<b>0506T</b>	Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report	EIU	2/21/2023
<b>0507T</b>	Near-infrared dual imaging (ie, simultaneous reflective and transilluminated light) of meibomian glands, unilateral or bilateral, with interpretation and report	EIU	2/21/2023
<b>0508T</b>	Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia	EIU	2/21/2023
<b>0510T</b>	Removal of sinus tarsi implant	EIU	2/21/2023
<b>0511T</b>	Removal and reinsertion of sinus tarsi implant	EIU	2/21/2023
<b>0515T</b>	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])	EIU	2/21/2023



## Experimental & Investigational Services Medical Necessity Guideline

<b>0516T</b>	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only	EIU	2/21/2023
<b>0517T</b>	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only	EIU	2/21/2023
<b>0518T</b>	Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing	EIU	2/21/2023
<b>0519T</b>	Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter)	EIU	2/21/2023
<b>0520T</b>	Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode	EIU	2/21/2023
<b>0521T</b>	Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing	EIU	2/21/2023
<b>0522T</b>	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing	EIU	2/21/2023
<b>0524T</b>	Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring	EIU	2/21/2023
<b>0525T</b>	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

<b>0526T</b>	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only	EIU	2/21/2023
<b>0527T</b>	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only	EIU	2/21/2023
<b>0528T</b>	Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report	EIU	2/21/2023
<b>0529T</b>	Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report	EIU	2/21/2023
<b>0530T</b>	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation, complete system (electrode and implantable monitor)	EIU	2/21/2023
<b>0531T</b>	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation, electrode only	EIU	2/21/2023
<b>0532T</b>	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation, implantable monitor only	EIU	2/21/2023
<b>0544T</b>	Transcatheter mitral valve annulus reconstruction, with implantation of adjustable annulus reconstruction device, percutaneous approach including transseptal puncture	EIU	2/21/2023
<b>0546T</b>	Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report	EIU	2/21/2023
<b>0552T</b>	Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional	EIU	2/21/2023
<b>0559T</b>	Anatomic model 3D-printed from image data set(s); first individually prepared and processed component of an anatomic structure	EIU	2/21/2023
<b>0560T</b>	Anatomic model 3D-printed from image data set(s); each additional individually prepared and	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

	processed component of an anatomic structure (List separately in addition to code for primary procedure)		
<b>0561T</b>	Anatomic guide 3D-printed and designed from image data set(s); first anatomic guide	EIU	2/21/2023
<b>0562T</b>	Anatomic guide 3D-printed and designed from image data set(s); each additional anatomic guide (List separately in addition to code for primary procedure)	EIU	2/21/2023
<b>0563T</b>	Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral	EIU	2/21/2023
<b>0583T</b>	Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia	EIU	2/21/2023
<b>0627T</b>	Percutaneous injection of allogeneic cellular and/or tissuebased product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level	EIU	2/21/2023
<b>0628T</b>	Percutaneous injection of allogeneic cellular and/or tissuebased product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure)	EIU	2/21/2023
<b>0629T</b>	Percutaneous injection of allogeneic cellular and/or tissuebased product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level	EIU	2/21/2023
<b>0630T</b>	Percutaneous injection of allogeneic cellular and/or tissuebased product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure)	EIU	2/21/2023
<b>0631T</b>	Transcutaneous visible light hyperspectral imaging measurement of oxyhemoglobin, deoxyhemoglobin, and tissue oxygenation, with interpretation and report, per extremity	EIU	2/21/2023
<b>0640T</b>	Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); image acquisition, interpretation and report, each flap or wound	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

<b>0641T</b>	Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO <sub>2</sub> ]); image acquisition only, each flap or wound	EIU	2/21/2023
<b>0642T</b>	Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO <sub>2</sub> ]); interpretation and report only, each flap or wound	EIU	2/21/2023
<b>0651T</b>	Magnetically controlled capsule endoscopy, esophagus through stomach, including intraprocedural positioning of capsule, with interpretation and report	EIU	2/21/2023
<b>0658T</b>	Electrical impedance spectroscopy of 1 or more skin lesions for automated melanoma risk score	EIU	2/21/2023
<b>0664T</b>	Donor hysterectomy (including cold preservation); open, from cadaver donor	EIU	2/21/2023
<b>0665T</b>	Donor hysterectomy (including cold preservation); open, from living donor	EIU	2/21/2023
<b>0666T</b>	Donor hysterectomy (including cold preservation); laparoscopic or robotic, from living donor	EIU	2/21/2023
<b>0667T</b>	Donor hysterectomy (including cold preservation); recipient uterus allograft transplantation from cadaver or living donor	EIU	2/21/2023
<b>0668T</b>	Backbench standard preparation of cadaver or living donor uterine allograft prior to transplantation, including dissection and removal of surrounding soft tissues and preparation of uterine vein(s) and uterine artery(ies), as necessary	EIU	2/21/2023
<b>0669T</b>	Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; venous anastomosis, each	EIU	2/21/2023
<b>0670T</b>	Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; arterial anastomosis, each	EIU	2/21/2023
<b>0672T</b>	Endovaginal cryogen-cooled, monopolar radiofrequency remodeling of the tissues surrounding the female bladder neck and proximal urethra for urinary incontinence	EIU	2/21/2023

## Experimental & Investigational Services Medical Necessity Guideline

<b>0691T</b>	Automated analysis of an existing computed tomography study for vertebral fracture(s), including assessment of bone density when performed, data preparation, interpretation, and report (Unnamed Zebra Medical/Nanox product)	EIU	2/21/2023
<b>0692T</b>	Therapeutic ultrafiltration	EIU	2/21/2023
<b>0694T</b>	3-dimensional volumetric imaging and reconstruction of breast or axillary lymph node tissue, each excised specimen, 3-dimensional automatic specimen reorientation, interpretation and report, realtime intraoperative	EIU	2/21/2023
<b>0714T</b>	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance	EIU	2/21/2023
<b>0735T</b>	Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with primary craniotomy (List separately in addition to code for primary procedure)	EIU	2/21/2023



## Experimental & Investigational Services Medical Necessity Guideline

### REGULATORY NOTES:

Medical Necessity Guidelines are published to provide a better understanding of the basis upon which coverage decisions are made. CCA makes coverage decisions on a case-by-case basis considering the individual member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the appropriate field, review of FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions. If at any time a CMS Local or National Coverage Determination (LCD or NCD) is published that conflicts with the criteria set forth herein, the NCD or LCD criteria shall supersede these criteria.

### Disclaimer:

This Medical Necessity Guideline is not a rigid rule. As with all of CCA's criteria, the fact that a member does not meet these criteria does not, in and of itself, indicate that no coverage can be issued for these services. Providers are advised, however, that if they request services for any member who they know does not meet our criteria, the request should be accompanied by clear and convincing documentation of medical necessity. The preferred type of documentation is the letter of medical necessity, indicating that a request should be covered either because there is supporting science indicating medical necessity (supporting literature (full text preferred) should be attached to the request), or describing the member's unique clinical circumstances, and describing why this service or supply will be more effective and/or less costly than another service which would otherwise be covered. Note that both supporting scientific evidence and a description of the member's unique clinical circumstances will generally be required.

### RELATED REFERENCES:

- Centers for Medicare & Medicaid Services. (2014). *Guidance for the public, industry, and CMS staff: Coverage with evidence development*. Retrieved from <https://www.cms.gov/medicare-coverage-database/details/medicare-coverage-document-details.aspx?MCDId=27>
- Centers for Medicare & Medicaid Services. (2014). *Medicare benefit policy manual: Chapter 14 medical devices*. Retrieved from <https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/bp102c14.pdf>
- Centers for Medicare & Medicaid Services. (2015). *Local coverage article: Clinical trials – Medical policy article (A52840)*. Retrieved from <https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=52840&ver=2&DocID=A52840&bc=gAAAABAAAA&>
- Centers for Medicare & Medicaid Services. (n.d.). *Medicare & clinical research studies*. Retrieved from <https://www.medicare.gov/Pubs/pdf/02226-medicare-and-clinical-research-studies.pdf>

### REVISION LOG:

REVISION DATE	DESCRIPTION



## Experimental & Investigational Services Medical Necessity Guideline

7/13/24	Removed CPT Q4121, Q4165, Q4199, Q4251, Q4252, Q4253. Effective 7/13/24, covered with prior authorization.
5/9/24	Removed CPT 97014, covered with prior authorization PT and OT services. Removed CPT 64568. CPT 61885 and 61886 covered for ICD 10-CM F32.0-F32.5 and F33.0-F33.3.
1/1/24	HCPCS code K1006 replaced by HCPCS code E2001
12/31/23	Approved by Utilization Management Committee
11/9/23	Removed CPT code 76981
10/12/23	Added CPT code 22505
4/13/2023	Removed codes G0283, 37243, 56620, 64585, 64910, and 90868. Added additional codes to the list.
1/11/2023	Added a column "Last Review Date" to the Code Chart in the Authorization Section.
1/4/2023	Added iovera as an Experimental and Investigational Service. CPT codes 64640 and 64624 were added.
6/2/2022	Removed CPT and HCPCS codes 33289, 93264, C2624 as MassHealth. Templated updated.
8/4/2021	Overview: Added greater detail to the definition of EIS. Definitions added: Authoritative or reliable evidence, clinical trial, experimental/investigation/unproven services, generally accepted standards of medical practice, medical necessary, net health outcome, not medically necessary, routine costs (in the context of clinical trials). Decision guidelines added: criteria when EIS is not covered and covered, coverage of routine costs for EIS in clinical trials.
5/18/2021	Added in the overview: the review of information from appropriate government regulatory bodies: CMS, Commonwealth of Massachusetts, and FDA.
5/13/2021	Removed CPT codes 0194T and 64566 as there are LCD coverage. Added CardioMEMs as an Experimental and Investigational Service. CPT codes 33289 and 93264, and HCPCS code C2624 added. Added HCPCS code (K1006) for the PureWick Systems.
8/26/2020	Updated approval signature

**APPROVALS:**

David Mello, DO  
\_\_\_\_\_  
**CCA Senior Clinical Lead [Print]**

*David Mello*  
\_\_\_\_\_  
**Signature**

Senior Medical Director  
\_\_\_\_\_  
**Title [Print]**

12/22/23  
\_\_\_\_\_  
**Date**

Nazlim Hagmann, MD  
\_\_\_\_\_  
**CCA CMO or Designee [Print]**

*Nazlim Hagmann*  
\_\_\_\_\_  
**Signature**

Chief Medical Officer  
\_\_\_\_\_  
**Title [Print]**

12/22/23  
\_\_\_\_\_  
**Date**